ABSCIENCES (EPA:AB) | Finanzwire

Basculer en Français

10794	Companies
233195	Keywords
161789	Articles
124395	Press releases

Home
Companies
ABSCIENCES

BRIEF

published on 01/29/2025 at 19:08, 1 year 6 months ago

AB Science Updates on Masitinib Platform Progress

Multiple Sclerosis Masitinib Platform ALS Study Alzheimer’s Treatment AB Science Strategy
PRESS RELEASE

published on 01/29/2025 at 19:03, 1 year 6 months ago

AB Science today provides an update on its masitinib platform
AB Science provides update on masitinib platform for ALS, MS, and AD. Positive results show potential for huge market sales. Debt negotiation planned

Update AB Science Masitinib Platform Market Sales Debt Negotiation
BRIEF

published on 01/24/2025 at 18:06, 1 year 6 months ago

AB Science to Present Masitinib Update in Upcoming Webcast

Pharmaceuticals Webcast Research Update AB Science Masitinib
PRESS RELEASE

published on 01/24/2025 at 18:01, 1 year 6 months ago

AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET
AB Science to host live webcast on masitinib platform update on January 28, 2025, 5.30pm CET. Leading pharmaceutical company specializing in protein kinase inhibitors

Pharmaceutical Company Live Webcast AB Science Protein Kinase Inhibitors Masitinib Platform
BRIEF

published on 01/22/2025 at 19:04, 1 year 6 months ago

AB Science Participates in Biomed Forum Investors Conference

Investor Conference BIOMED Forum AB Science Masitinib Protein Kinase Inhibitors
PRESS RELEASE

published on 01/22/2025 at 18:59, 1 year 6 months ago

AB Science will participate in the Biomed Forum investors conference
AB Science to participate in Biomed Forum Investors Conference organized by AllInvest Securities in Paris on February 4, 2025

Pharmaceutical Company BIOMED Forum AB Science Investors Conference AllInvest Securities
BRIEF

published on 12/17/2024 at 19:09, 1 year 7 months ago

AB Science presents the advances of AB8939 for acute myeloid leukemia

Phase 1 AB8939 Acute Myeloid Leukemia Drug Resistance Potential Market
PRESS RELEASE

published on 12/17/2024 at 19:04, 1 year 7 months ago

AB Science provides a summary of the webcast held on December 16, 2024
AB Science provides an update on AB8939, a novel microtubule destabilizer and ALDH inhibitor in phase 1 for AML treatment. Potential market size exceeded EUR 2 billion per annum

Market Potential AML Treatment AB Science Phase 1 AB8939
BRIEF

published on 10/17/2024 at 19:33, 1 year 9 months ago

AB Science Faces Setback in EMA Approval for ALS Treatment

AB Science Masitinib Marketing Authorization ALS Treatment EMA Decision
PRESS RELEASE

published on 10/17/2024 at 19:28, 1 year 9 months ago

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
AB Science provides an update on the application for conditional marketing authorisation of masitinib in the treatment of amyotrophic lateral sclerosis. EMA confirms negative opinion but company remains focused on confirmatory phase 3 program

Phase 3 Program AB Science Masitinib Amyotrophic Lateral Sclerosis Conditional Marketing Authorisation

Accesswire

Published on 08/01/2026 at 01:20, 2 days 5 hours ago

Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 2 days 5 hours ago

Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 2 days 6 hours ago

Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 08/01/2026 at 00:25, 2 days 6 hours ago

BioNxt Solutions Announces Option Grants
Published on 07/31/2026 at 23:20, 2 days 7 hours ago

Pentagon I Capital Corp. Announces Conditional Acceptance of Qualifying Transaction with Prospectiva Resources Ltd.

View all ACCESSWIRE

EQS Group

Published on 08/03/2026 at 07:00, 11 minutes ago

Sandoz takes further steps to resolve legacy US generic medicine litigation
Published on 08/03/2026 at 07:00, 11 minutes ago

Stabilus SE: Adjusted EBIT margin increased in Q3 FY2026 despite a decline in revenue – sale of Fabreeka and Tech Products completed and net debt further reduced
Published on 08/03/2026 at 07:00, 11 minutes ago

AEVIS VICTORIA SA (AEVS.SW) – MRH Switzerland AG continues to grow and outperforms the Swiss hotel market in the first half of 2026
Published on 08/03/2026 at 06:45, 26 minutes ago

HDBank secures record international syndicated social loan in Vietnam
Published on 08/03/2026 at 06:30, 41 minutes ago

HDBank posts 31% rise in first-half profit, assets exceed VND1 quadrillion

Les Echos

Published on 08/03/2026 at 07:00, 11 minutes ago

BIOPHYTIS PROVIDES AN UPDATE AND SHARE STRATEGIC DRIVERS SUPPORTING ITS HONG KONG JOINT VENTURE
Published on 07/31/2026 at 21:00, 2 days 10 hours ago

Carrefour completes the sale of its minority stake in CarrefourSA in Turkey to Yeni Mağazacılık A.Ş., operator of the A101 retail chain and controlled by the Aydın Group
Published on 07/31/2026 at 19:27, 2 days 11 hours ago

Share retention commitments (Dutreil Agreement)
Published on 07/31/2026 at 19:14, 2 days 11 hours ago

2026 First-Half financial report
Published on 07/31/2026 at 19:13, 2 days 11 hours ago

Covivio - Information on Treasury shares transactions between July 29th, 2026 and July 31st, 2026

View all LES ECHOS COMFI WIRE